Profund Advisors LLC raised its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 19.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,971 shares of the biopharmaceutical company’s stock after acquiring an additional 2,558 shares during the period. Profund Advisors LLC’s holdings in Agios Pharmaceuticals were worth $822,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in AGIO. Bank of Montreal Can boosted its holdings in Agios Pharmaceuticals by 11.7% during the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 216 shares during the period. Blue Sky Asset Management LLC bought a new stake in Agios Pharmaceuticals during the first quarter valued at about $129,000. Russell Investments Group Ltd. boosted its holdings in Agios Pharmaceuticals by 163.9% during the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 1,583 shares during the period. Aperio Group LLC bought a new stake in Agios Pharmaceuticals during the second quarter valued at about $206,000. Finally, Soros Fund Management LLC bought a new stake in Agios Pharmaceuticals during the first quarter valued at about $228,000. Institutional investors own 94.40% of the company’s stock.

WARNING: This report was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/09/24/agios-pharmaceuticals-inc-agio-holdings-raised-by-profund-advisors-llc.html.

In related news, CEO David P. Schenkein sold 3,000 shares of Agios Pharmaceuticals stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $51.18, for a total transaction of $153,540.00. Following the completion of the sale, the chief executive officer now owns 3,000 shares of the company’s stock, valued at approximately $153,540. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction dated Friday, July 7th. The stock was sold at an average price of $55.00, for a total transaction of $118,030.00. Following the sale, the insider now directly owns 8,410 shares of the company’s stock, valued at approximately $462,550. The disclosure for this sale can be found here. Insiders have sold a total of 134,938 shares of company stock valued at $8,359,112 in the last ninety days. 10.55% of the stock is currently owned by insiders.

Agios Pharmaceuticals, Inc. (NASDAQ AGIO) opened at 66.07 on Friday. Agios Pharmaceuticals, Inc. has a 12 month low of $39.24 and a 12 month high of $67.74. The stock’s 50 day moving average is $60.83 and its 200-day moving average is $54.73. The firm’s market cap is $3.20 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the consensus estimate of ($1.57) by ($0.21). The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The business’s quarterly revenue was up 62.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.47) EPS. On average, analysts anticipate that Agios Pharmaceuticals, Inc. will post ($7.07) earnings per share for the current fiscal year.

A number of equities research analysts have issued reports on the stock. J P Morgan Chase & Co restated a “buy” rating and set a $76.00 price target on shares of Agios Pharmaceuticals in a report on Monday, September 18th. Royal Bank Of Canada assumed coverage on shares of Agios Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price target for the company. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 2nd. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Finally, Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $83.00 price target (up from $75.00) on shares of Agios Pharmaceuticals in a report on Thursday, August 10th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $75.20.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.